Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $20.00 Price Target at Robert W. Baird

Enanta Pharmaceuticals (NASDAQ:ENTA) had its target price cut by Robert W. Baird from $26.00 to $20.00 in a report published on Tuesday morning,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

A number of other analysts have also recently commented on the company. Evercore ISI upgraded Enanta Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. JPMorgan Chase & Co. cut their price target on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a report on Tuesday, August 6th. Finally, JMP Securities reissued a “market outperform” rating and set a $21.00 price target (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $19.50.

Enanta Pharmaceuticals Price Performance

ENTA stock opened at $8.56 on Tuesday. Enanta Pharmaceuticals has a 1-year low of $8.00 and a 1-year high of $17.80. The business has a fifty day moving average price of $10.97 and a 200-day moving average price of $12.33. The stock has a market capitalization of $181.38 million, a P/E ratio of -1.57 and a beta of 0.56.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC raised its position in Enanta Pharmaceuticals by 3.5% during the first quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock valued at $36,579,000 after purchasing an additional 70,000 shares during the period. Vanguard Group Inc. raised its holdings in shares of Enanta Pharmaceuticals by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock worth $33,664,000 after buying an additional 134,292 shares during the period. Krensavage Asset Management LLC raised its holdings in shares of Enanta Pharmaceuticals by 19.7% in the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock worth $15,520,000 after buying an additional 246,736 shares during the period. Geode Capital Management LLC raised its holdings in shares of Enanta Pharmaceuticals by 3.1% in the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock worth $4,946,000 after buying an additional 14,575 shares during the period. Finally, State Street Corp raised its holdings in shares of Enanta Pharmaceuticals by 6.4% in the third quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock worth $4,662,000 after buying an additional 27,147 shares during the period. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.